Costs of multimorbidity: a systematic review and meta-analyses
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Multimorbidity is a rising global phenomenon, placing strains on countries’ population health and finances. This systematic review provides insight into the costs of multimorbidity through addressing the following primary and secondary research questions: What evidence exists on the costs of multimorbidity? How do costs of specific disease combinations vary across countries? How do multimorbidity costs vary across disease combinations? What “cost ingredients” are most commonly included in these multimorbidity studies? Methods: We conducted a systematic review (PROSPERO: CRD42020204871) of studies published from January 2010 to January 2022, which reported on costs associated with combinations of at least two specified conditions. Systematic string-based searches were conducted in MEDLINE, The Cochrane Library, SCOPUS, Global Health, Web of Science, and Business Source Complete. We explored the association between costs of multimorbidity and country Gross Domestic Product (GDP) per capita using a linear mixed model with random intercept. Annual mean direct medical costs per capita were pooled in fixed-effects meta-analyses for each of the frequently reported dyads. Costs are reported in 2021 International Dollars (I$). Results: Fifty-nine studies were included in the review, the majority of which were from high-income countries, particularly the United States. (1) Reported annual costs of multimorbidity per person ranged from I$800 to I$150,000, depending on disease combination, country, cost ingredients, and other study characteristics. (2) Our results further demonstrated that increased country GDP per capita was associated with higher costs of multimorbidity. (3) Meta-analyses of 15 studies showed that on average, dyads which featured Hypertension were among the least expensive to manage, with the most expensive dyads being Respiratory and Mental Health condition (I$36,840), Diabetes and Heart/vascular condition (I$37,090), and Cancer and Mental Health condition in the first year after cancer diagnosis (I$85,820). (4) Most studies reported only direct medical costs, such as costs of hospitalization, outpatient care, emergency care, and drugs. Conclusions: Multimorbidity imposes a large economic burden on both the health system and society, most notably for patients with cancer and mental health condition in the first year after cancer diagnosis. Whether the cost of a disease combination is more or less than the additive costs of the component diseases needs to be further explored. Multimorbidity costing studies typically consider only a limited number of disease combinations, and few have been conducted in low- and middle-income countries and Europe. Rigorous and standardized methods of data collection and costing for multimorbidity should be developed to provide more comprehensive and comparable evidence for the costs of multimorbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092
Forouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Gelman, A. (2006) · Bayesian Analysis · doi:10.1214/06-ba117a · Cited by 4,050
Violan, C., Foguet-Boreu, Q., Flores-Mateo, G., Salisbury, C., Blom, J., Freitag, M., Glynn, L., Muth, C., & Valderas, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102149 · Cited by 1,125
Prevalence of multimorbidity among adults seen in family practice
Fortin, M. (2005) · The Annals of Family Medicine · doi:10.1370/afm.272 · Cited by 987
Review of statistical methods for analysing healthcare resources and costs
Mihaylova, B., Briggs, A., O'Hagan, A., & Thompson, S. G. (2011) · Health Economics · doi:10.1002/hec.1653 · Cited by 767
A Systematic Review of Cost-of-Illness Studies of Multimorbidity
Wang, L., Si, L., Cocker, F., Palmer, A. J., & Sanderson, K. (2018) · Applied Health Economics and Health Policy · doi:10.1007/s40258-017-0346-6 · Cited by 178
Egede, L. E., Walker, R. J., Bishu, K., & Dismuke, C. E. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3650-1 · Cited by 70
Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity
Boye, K. S., Lage, M. J., & Terrell, K. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107730 · Cited by 30
Mausbach, B. T., Bos, T., & Irwin, S. A. (2018) · Health Psychology · doi:10.1037/hea0000670 · Cited by 27
Cited by
COPD and multimorbidity: Recognising and addressing a syndemic occurrence
Fabbri, L. M., Celli, B. R., Agustí, A., Criner, G. J., Dransfield, M. T., Divo, M., Krishnan, J. K., Lahousse, L., Montes de Oca, M., Salvi, S. S., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00261-8 · Cited by 274
Metadata
- Authors
- Tran, P. B., Kazibwe, J., Nikolaidis, G. F., Linnosmaa, I., Rijken, M., & van Olmen, J.
- Venue
- BMC Medicine
- Published
- 2022-07-19
- Volume
- 20
- Issue
- 1
- Pages
- 234-234
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W4285799273
- Cited by
- 192
- References
- 10
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Costs of multimorbidity: a systematic review and meta-analyses. https://app.cochat.ai/papers/10.1186/s12916-022-02427-9
- The paper
- Tran, P. B., Kazibwe, J., Nikolaidis, G. F., Linnosmaa, I., Rijken, M., & van Olmen, J. (2022). Costs of multimorbidity: a systematic review and meta-analyses. BMC Medicine. https://doi.org/10.1186/s12916-022-02427-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.